具体来看，今日上榜的营业部中，共有4家机构专用席位现身，即卖一、卖二、卖四、卖五，合计买入 金额799.19万元，卖出金额7783.47万元，合计净卖出6984.29万元，深股通为第一大买入营业部，买入 金额为2540.10万元，卖出金额为53.75万元，合计净买入2486.35万元。 资金流向方面，今日该股主力资金净流出4456.65万元，其中，特大单净流出3322.96万元，大单资金净 流出1133.69万元。近5日主力资金净流入193.12万元。 融资融券数据显示，该股最新（12月26日）两融余额为1.86亿元，其中，融资余额为1.85亿元，融券余 额为40.81万元。近5日融资余额合计增加5132.55万元，增幅为38.33%，融券余额合计增加0.82万元，增 幅2.04%。（数据宝） 漱玉平民今日下跌17.91%，全天换手率19.80%，成交额7.67亿元，振幅11.33%。龙虎榜数据显示，机构 净卖出6984.29万元，深股通净买入2486.35万元，营业部席位合计净买入153.65万元。 深交所公开信息显示，当日该股因日收盘价跌幅达-17.91%上榜，机构专用席位净卖出6984.29万元，深 股 ...

12月26日，大参林（维权）涨0.39%，成交额7038.59万元。两融数据显示，当日大参林获融资买入额 273.80万元，融资偿还852.88万元，融资净买入-579.08万元。截至12月26日，大参林融资融券余额合计 2.16亿元。 资料显示，大参林医药集团股份有限公司位于广东省广州市荔湾区龙溪大道410号、410-1号，成立日期 1999年2月12日，上市日期2017年7月31日，公司主营业务涉及中西成药、参茸滋补药材及中药饮片、保 健品、医疗器械及其他商品的连锁零售业务。主营业务收入构成为：中西成药79.08%，非药品 10.87%，中参药材10.05%。 截至9月30日，大参林股东户数2.86万，较上期减少9.38%；人均流通股39833股，较上期增加10.35%。 2025年1月-9月，大参林实现营业收入200.68亿元，同比增长1.71%；归母净利润10.81亿元，同比增长 25.97%。 融券方面，大参林12月26日融券偿还1.27万股，融券卖出300.00股，按当日收盘价计算，卖出金额 5436.00元；融券余量26.22万股，融券余额475.11万元，超过近一年80%分位水平，处于高位。 ...

证券日报网讯12月19日晚间，健之佳（605266）发布公告称，截至本公告披露日，公司不存在逾期对外 担保。 ...

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交会额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-12-17 | 002727 | 一心堂 | 11.25 | 21.07 | 237.04 | 中信证券华南股份 | 中国中金财富证券 | | | | | | | | 有限公司云南分公 | 有限公司大连星海 | | | | | | | | Ta | 广场证券营业部 | | 2025-12-17 | 002727 | 一心堂 | 11.25 | 75.29 | 847.01 | 中信证券华南股份 | 中信证券华南股份 | | | | | | | | 有限公司云南分公 | 有限公司云南分公 | | | | | | | | n | Ti | | 2025-12-17 | 002727 | 一心堂 | 11.25 | 46.32 | 521.10 | 中信证券华南股份 | 国泰海通证券股份 | | | | | | | | ...

Policy Developments - Jiangxi Province has introduced 13 measures to promote the high-quality development of the pharmaceutical retail chain industry, including support for enterprise integration, simplified approval processes, and encouragement of innovative business models [1] - The new policies aim to address industry pain points, such as supporting mergers and acquisitions, and promoting health service extensions like chronic disease management [1] Medical Device Approvals - The National Medical Products Administration has approved two innovative medical devices: a proton therapy system for treating malignant tumors and a deep brain stimulation system for opioid addiction treatment [2] Clinical Trials - Haikang announced that its subsidiary received clinical trial approval for four innovative drugs targeting inflammatory bowel disease, respiratory diseases, acute pain, and muscular dystrophy [3] Capital Market Developments - Changchun High-tech signed an exclusive licensing agreement for the GenSci098 injection project, potentially earning up to $1.365 billion in milestone payments [4][5] Industry Collaborations - Sunshine Nuohuo has partnered with Peking University to establish a joint laboratory focused on innovative drug development, particularly in cell and gene therapy [7] Regulatory Actions - The Shanghai Consumer Protection Committee has addressed issues related to Antarctic krill oil products from Beijing Tongrentang, highlighting quality control failures and potential misrepresentation [10][11]

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The Chinese chain pharmacy industry is experiencing rapid growth, with the market size expected to exceed 1 trillion yuan by the end of 2024, indicating significant market potential [18] - The industry has maintained an average annual growth rate of over 10% in the past five years, driven by increased medical insurance coverage and rising consumer health awareness [20] - The market is becoming increasingly concentrated, with leading companies like Guoda Pharmacy, Yifeng Pharmacy, and Laobaixing Pharmacy dominating the market [39] Industry Overview - The chain pharmacy industry is defined as a collection of retail stores organized under a unified management system, sharing brand image, procurement channels, and service processes [4] - The industry has evolved from traditional single-store pharmacies to a more standardized and professional model, with significant growth in major cities [8] - The industry is categorized into three main types: direct chain pharmacies, franchise chain pharmacies, and mixed chain pharmacies [5] Market Size and Growth Trends - As of 2024, the number of chain pharmacy stores in China has surpassed 120,000, covering most provinces and major cities [18] - The industry is characterized by a "leading enterprises leading, regional strong players supporting" market structure, with significant market share held by top companies [18][39] - The growth of the industry is supported by government policies promoting healthcare consumption and capital market interest [10] Supply and Demand Analysis - Major chain pharmacy enterprises are concentrated in first-tier cities and economically developed second-tier cities, with a notable presence in eastern coastal regions [21] - The supply chain and logistics systems are crucial for improving operational efficiency and ensuring drug safety [24] - The variety of drugs offered includes prescription drugs, over-the-counter drugs, traditional Chinese medicine, and health products, catering to diverse consumer needs [26] Consumer Behavior and Preferences - The primary consumer groups include elderly patients with chronic diseases, young health management consumers, and families with regular medication needs [28] - Modern consumers prioritize drug quality, price transparency, and overall service experience, leading to a shift towards personalized health management services [31] - The integration of online and offline purchasing channels is becoming the mainstream trend in the pharmaceutical retail industry [34] Competitive Landscape - Leading companies like Guoda Pharmacy, Yifeng Pharmacy, and Laobaixing Pharmacy dominate the market, leveraging their financial strength and efficient supply chain management [37] - The market is highly concentrated, with the top ten chain pharmacies holding over half of the market share [39] - Regional competition varies, with intense competition in economically developed areas and significant growth potential in less developed regions [42] Policy and Regulatory Environment - The government has implemented strict regulations to ensure drug quality and safety, including licensing requirements and procurement standards [48] - Recent reforms in medical insurance policies have significantly impacted the operations of chain pharmacies, prompting them to optimize procurement and inventory management [50] - Regulatory measures are aimed at promoting standardized and compliant operations within the industry [51] Technological Development and Digital Transformation - The application of information technology, such as drug management information systems and customer relationship management (CRM) systems, is enhancing operational efficiency [58][59] - The integration of mobile payment and electronic prescriptions is transforming the purchasing process, improving customer experience [61] - The trend towards online and offline integration is driving the development of a comprehensive sales and service system [62]

一心堂12月15日大宗交易平台共发生2笔成交，合计成交量460.00万股，成交金额5207.20万元。成交价 格均为11.32元，相对今日收盘价折价9.87%。 证券时报·数据宝统计显示，一心堂今日收盘价为12.56元，平盘报收，日换手率为1.06%，成交额为 5254.02万元，全天主力资金净流入4.41万元，近5日该股累计下跌3.46%，近5日资金合计净流出1071.70 万元。 | 成交量 （万股） | 成交金额 （万元） | 成交价格 （元） | 相对当日收盘折 溢价（%） | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | 230.00 | 2603.60 | 11.32 | -9.87 | 中信证券华南股份有限 | 中信证券华南股份有限 | | | | | | 公司云南分公司 | 公司云南分公司 | | 230.00 | 2603.60 | 11.32 | -9.87 | 中信证券华南股份有限 | 中信证券华南股份有限 | | | | | | 公司云南分公司 | 公司云南分公司 | （文章来源：证券时报网） 两融数据显示，该股最新融资 ...

（文章来源：证券日报） 证券日报网讯 12月12日，老百姓在互动平台回答投资者提问时表示，公司2025年第三季度营业收入 52.96亿元，同比增长0.07%，归母净利润1.31亿元、同比增长2.6%，均已转正增长，经营业绩逐季改 善、持续向好。在行业整合出清的背景下，公司持续夯实经营质量，努力实现更好的经营业绩，回报投 资者。在美妆护肤领域，公司一方面引进优质护肤品牌产品强强联合；另一方面打造公司自有品牌美妆 护肤性价比商品，包括面膜、胶原蛋白辅料等。 ...

（记者 曾健辉） 每经头条（nbdtoutiao）——最新1520元，飞天茅台批价两年跌了43%，经销商躺赢神话破灭，当潮水 退去谁在裸泳？ 每经AI快讯，漱玉平民12月10日晚间发布公告称，公司第四届第十四次董事会会议于2025年12月10日 在公司会议室以现场结合通讯表决的方式召开。会议审议了《关于拟变更会计师事务所的议案》等文 件。 ...

Core Viewpoint - The company reported a steady improvement in its operational performance for Q3 2025, with revenue and net profit showing slight year-on-year growth, while also addressing the increased health demands due to a flu outbreak by ensuring stable supply of essential medications and protective supplies [1]. Group 1: Financial Performance - For Q3 2025, the company achieved a revenue of 5.296 billion yuan, representing a year-on-year growth of 0.07%, and a net profit attributable to shareholders of 131 million yuan, reflecting a year-on-year increase of 2.6% [1]. - The company has a total of 15,492 stores across 18 provincial markets and over 150 cities, with 9,741 being direct-operated and 5,751 being franchised [1]. Group 2: Supply Chain and Product Strategy - In response to the surge in health demands, the company leveraged its nationwide supply chain and store network to ensure the availability of four key types of medications and protective supplies, with sufficient inventory and stable prices [1]. - Sales of the four key medication categories have seen a month-on-month increase since November [1]. Group 3: Online Business Strategy - The company is focusing on a "category king + seasonal explosive products" strategy to enhance its online business competitiveness, transitioning from quantity to quality [2]. - Key initiatives include refined operations in core business districts using AI and automation, and a marketing platform shift from manual to data-driven management [2]. Group 4: Store Transformation and Customer Experience - The company has initiated a dual-line transformation of its stores, shifting from a transactional to a relational model, aiming to transform staff into trusted health advisors to enhance customer experience [3]. - Measures to improve service quality include restructuring service philosophies, optimizing performance metrics, and enhancing training programs for frontline staff [3]. Group 5: Industry Trends and Challenges - The industry is experiencing accelerated consolidation, with a net decrease of 3,166 stores in Q1 and 4,002 stores in Q2 of 2025, leading to a total of 695,000 stores [4]. - Stricter healthcare policies are pushing for higher compliance and quality in the industry, resulting in the exit of smaller, less compliant players, while larger chains are expected to benefit from this consolidation [4]. - The company aims to capitalize on these industry changes by integrating resources through franchising and alliances to increase market share [4].